Increasingly Specialized Clinical Trials Accelerate Advances in NSCLC Management
November 27th 2023Subgroup analyses from non–small cell lung cancer clinical trials, such as the phase 3 POSEIDON and FLAURA2 trials, can help personalize treatment decisions with immunotherapy and targeted therapy based on individual mutational profiles.
Dr Birrer on Molecular Stratification in Endometrial Cancer
September 8th 2023Michael J. Birrer, MD, PhD, discusses the benefits of molecular profiling in patients with endometrial cancer, the variety of mutations that have been identified in this disease, and how stratifying patients based on the biomarkers their disease harbors allows for more individualized treatment decisions.
Dendritic Cell Vaccines Represent Potential Avenue to Enhance Immunotherapy in Ovarian Cancer
Martin Cannon, PhD, delves into ongoing research on the use of dendritic cell vaccines to generate Th17 responses in patients with ovarian cancer and details how this could address a need for select patients with ovarian cancer.
Cracking the Immunotherapy Code Remains a Challenge in Ovarian Cancer
Martin Cannon, PhD, details the history of investigating immune checkpoint inhibitors in patients with ovarian cancer and expands on the questions that need to be answered to potentially improve the activity of these agents in this patient population.
Dr Williams on the Evolution of Treatment Approaches in Ovarian Cancer
August 30th 2023Heather R. Williams, MD, discusses the evolution of the ovarian cancer treatment paradigm over the past several decades, as well as the importance of continuing to investigate individualized treatment approaches in this population to expand therapeutic options after disease recurrence.
Dr Cannon on the Investigation of the Th17 Dendritic Cell Vaccine in Ovarian Cancer
August 23rd 2023Martin Cannon, PhD, discusses the phase 1 investigation of the Th17 dendritic cell vaccine in ovarian cancer, and how it could potentially improve suboptimal responses when treated with immunotherapy alone in this population.
Dr Williams on the Importance of Investigating ADCs in Ovarian Cancer
August 16th 2023Heather R. Williams, MD, discusses the importance of further exploring the use of antibody drug conjugates in ovarian cancer, specifically highlighting the investigation of mirvetuximab soravtansine in this population.
Immuno-Oncology Approaches Continue to Advance Across Gynecologic Cancers
July 11th 2023Michael J. Birrer, MD, PhD, highlights the effect of improved molecular characterization in endometrial cancer, the clinical significance of the KEYNOTE-775 trial, and recent changes in the frontline treatment landscape in advanced endometrial cancer.
Examining the Role of BTK Inhibitors in Mantle Cell Lymphoma
June 27th 2023As part of the diagnostic work-up for a patient with newly diagnosed MCL, it is important to establish prognostic disease biology factors such as classical nodal morphology vs blastoid variant vs leukemic variant, TP53 mutation status, and Ki-67 reflective of proliferation.
Leveraging BTK Inhibitors in Chronic Lymphocytic Leukemia
June 26th 2023The choice of BTK inhibitor regimen for patients with chronic lymphocytic leukemia must be tailored to the patient, taking into consideration their preferences and comorbidities, as well as potential treatment-related adverse effects.
Treatment Complexities Continue to Mount in Gynecologic Cancers
January 3rd 2023Data concerning the long-term benefit of PARP inhibitors as maintenance therapy for select patients with ovarian cancer in later-line settings have come under fire in 2022 as several agents have failed to demonstrate improvements in OS outcomes.
Pebbles Fagan, Ph.D., MPH, Joins Leadership Team at UAMS Winthrop P. Rockefeller Cancer Institute
September 23rd 2022Pebbles Fagan, Ph.D., MPH, has assumed the role of associate director for Cancer Prevention and Control for the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences.
Evolving Technology Behind ADCs Could Improve Benefit in Advanced Ovarian Cancer
Michael Birrer, MD, PhD, discusses how new technology has transformed ADCs, how upifitamab rilsodotin could have a role in treating patients with ovarian cancer, and why the NaPi2B biomarker could be a vital target.
Optimized Treatment Starts With Molecular Testing in NSCLC
January 14th 2022Konstantinos Arnaoutakis, MD, discusses new strategies in the management of ALK-positive non–small cell lung cancer, frontline immunotherapy, targeting EGFR, and biomarkers and targeted therapies in early-stage and advanced disease.